Home > Thoracic Oncology
    Content Type:
  • Thoracic Oncology

    An Introduction to Thoracic Oncology

    Although the incidence and mortality from lung cancer is decreasing in some Western countries due to decades of public education and tobacco control policies, it remains a major cause of mortality worldwide. The treatment landscape for non-small-cell lung cancer (NSCLC) has been transformed in the past decade, thanks to the development of immune checkpoint inhibitors targeting the programmed cell death-1 (PD-1), programmed cell death ligand-1 (PD-L1) and cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4), and therapies targeting specific genetic alterations.

    Expert video highlights and insights from the conference hub and comprehensive peer-reviewed articles from our journal portfolio provide updates on the ever changing landscape. To learn more about how the latest developments impact on patient outcomes view our expert-led learning activities

    Our supporting partners do not constitute an endorsement of the content on this page.

    Thoracic Oncology Content

    Copied to clipboard!
    accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greyarrow-right-orangearrow-right-whitearrow-right-blueavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar